Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

This study is ongoing, but not recruiting participants.

First Received on September 13, 2001. Last Updated on July 21, 2010 History of Changes

Sponsor:	University of California, Los Angeles
Collaborator:	National Cancer Institute (NCI)
Information provided by:	University of California, Los Angeles
ClinicalTrials.gov Identifier:	NCT00024076

Purpose

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Condition	Intervention	Phase
Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma	Procedure: radiofrequency ablation	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Radiofrequency Ablation of Pulmonary Malignancy

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer Mesothelioma

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Study Start Date:

July 2001

Detailed Description:

OBJECTIVES:

Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
Determine the efficacy of this treatment, in terms of local control, in these patients.
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of a primary or secondary intrathoracic malignancy
- Any cell type or origin
- Involving the intrapulmonary, mediastinal, or pleural/chest wall
- Inoperable primary or metastatic cancer to the lung
Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
Single or multiple lesions that are non-contiguous with vital structures or organs such as:
Trachea
Heart
Aorta
Great vessels
Esophagus
Less than 5 cm in largest dimension
Accessible via percutaneous transthoracic route
Hepatic:
- Coagulation profile normal

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00024076

Locations

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781

Sponsors and Collaborators

University of California, Los Angeles

National Cancer Institute (NCI)

Investigators

Study Chair:

Robert D. Suh, MD

Jonsson Comprehensive Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Robert Suh, University of California, Los Angeles
ClinicalTrials.gov Identifier:	NCT00024076 History of Changes
Other Study ID Numbers:	CDR0000068889, P30CA016042, UCLA-9908024, NCI-G01-2011
Study First Received:	September 13, 2001
Last Updated:	July 21, 2010
Health Authority:	United States: Federal Government

Keywords provided by University of California, Los Angeles:

recurrent non-small cell lung cancer
recurrent small cell lung cancer
recurrent malignant mesothelioma
recurrent thymoma and thymic carcinoma

stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
pulmonary carcinoid tumor
lung metastases

Additional relevant MeSH terms:

Carcinoma
Lung Neoplasms
Mesothelioma
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Thymoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Thoracic Neoplasms

Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Adenoma
Neoplasms, Mesothelial
Neoplastic Processes
Pathologic Processes
Neoplasms, Complex and Mixed
Thymus Neoplasms
Lymphatic Diseases

ClinicalTrials.gov processed this record on February 09, 2012